Sema4 Holdings Corp. The company is headquartered in Stamford, Connecticut.
| Revenue (TTM) | $454.43M |
| Gross Profit (TTM) | $315.30M |
| EBITDA | $-33.70M |
| Operating Margin | -15.20% |
| Return on Equity | -40.80% |
| Return on Assets | -7.89% |
| Revenue/Share (TTM) | $15.55 |
| Book Value | $8.19 |
| Price-to-Book | 7.87 |
| Price-to-Sales (TTM) | 4.09 |
| EV/Revenue | 4.304 |
| EV/EBITDA | 61.75 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 11.40% |
| Shares Outstanding | $29.82M |
| Float | $20.44M |
| % Insiders | 7.71% |
| % Institutions | 108.61% |
Volatility is currently contracting
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference ca.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights five areas: Scaling genomic interpretation with AI and machine learning: A GeneDx.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
GeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today reported its financial and operational results for the second quarter of 2026.
New York, New York--(Newsfile Corp. - August 3, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GeneDx securities between April 16, 2025 and May 4, 2026, both dates inclusive (the "Class Period").
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WGS and any ticker you trade — then tracks every position and per-strategy win rate.
